Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2016

Pratz Keith W, Koh Brian D, Patel Anand G, Flatten Karen S, Poh Weijie, Herman James G, Dilley Robert, Harrell Maria I, Smith B Douglas, Karp Judith E, Swisher Elizabeth M, McDevitt Michael A, Kaufmann Scott H

Abstract excerpt

PURPOSE: DNA repair defects have been previously reported in myeloproliferative neoplasms (MPN). Inhibitors of PARP have shown activity in solid tumors with defects in homologous recombination (HR). This study was performed to assess MPN sensitivity to PARP inhibitors ex vivo EXPERIMENTAL DESIGN: HR pathway integrity in circulating myeloid cells was evaluated by assessing the formation of RAD51 foci after...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Hypersensitivity

Share to Drug Tolerance

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Rad51 Recombinase

Source

Open in PubMed Open full text

Identifiers

PMID: 26979391
DOI: 10.1158/1078-0432.CCR-15-2351
PMCID: PMC5041297

Genes

RAD51
JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.PMID 26979391Read ↗

Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case seriesSemantic proximity Read ↗

PARP Inhibitors and Myeloid Neoplasms: A Double-Edged SwordSemantic proximity Read ↗

PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human CellsSemantic proximity Read ↗

Hematologic complications in patients exposed to PARP inhibitorsSemantic proximity Read ↗

Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies.Semantic proximity Read ↗

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic LeukemiaSemantic proximity Read ↗

The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma EffectsSemantic proximity Read ↗

PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.Semantic proximity Read ↗

In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.Semantic proximity Read ↗

Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination–Proficient Pancreatic CancerSemantic proximity Read ↗

Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumorsSemantic proximity Read ↗

PARP-inhibitor-induced synthetic lethality for acute myeloid leukemia treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.